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Abstract
Background ABCB4/MDR3 gene variants are mostly asso-
ciated with a peculiar form of cholelithiasis in European
adults, currently referred to as low phospholipid-associated
cholelithiasis (LPAC) syndrome.
Methods LPAC syndrome is a rare genetic disorder,
characterised by the following clinical features: biliary
symptoms before the age of 40, recurrence of the symptoms
after cholecystectomy, and intrahepatic microlithiasis or
intrahepatic hyperechogenic foci.
Results Imaging features associated with ABCB4/MDR3
mutations are not specific and correspond to a wide spectrum
of biliary abnormalities. The main feature is the presence of
intrahepatic lithiasis. Other uncommon presentations have
been described, such as uni- or multifocal spindle-shaped
dilatations of the intrahepatic bile ducts filled with gallstones,
secondary sclerosing cholangitis, biliary cirrhosis, and
intrahepatic cholangiocarcinoma.
Conclusion This review focuses on MR features related to
ABCB4/MDR3 mutations.
Main Messages
• LPAC syndrome is characterised by intrahepatic
microlithiasis or intrahepatic hyperechogenic foci.
• Ultrasound examination is very accurate in detecting
intrahepatic stones.
• At MR imaging, LPAC syndrome is associated with vari-
ous presentations.
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Introduction
In 1996, Deleuze et al. [1] initially suspected the role of
defects in the multidrug resistance 3 P-glycoprotein (MDR3)
in a subtype of progressive familial intrahepatic cholestasis
(PFIC). This refers to a heterogeneous group of familial cho-
lestatic conditions caused by defects in biliary epithelial trans-
porters. The disease usually occurs first in childhood with
progressive cholestasis leading to death from liver failure at
ages ranging from infancy to adolescence [2]. The underlying
genetic and molecular abnormalities related to PFIC have led
to the identification of three subtypes and the description of
several mutations in hepatocellular transport system genes
involved in bile formation. Only PFIC 3 can be related to
defects in the ABCB4 gene encoding MDR3. MDR3 is a
phospholipid translocator involved in biliary phosphatidyl-
choline excretion. The result of these mutations is a reduced
amount of phosphatidylcholine in bile. Phosphatidylcholine
solubilises cholesterol in mixed micelles and prevents
damage to the biliary epithelium from unbound bile acids.
The ‘unchaperoned’ bile acids in the bile of patients with
MDR3 deficiency may cause chronic cholangitis. Several
other biliary disorders have been associated with
ABCB4/MDR3 mutations: low phospholipid-associated
cholelithiasis (LPAC) syndrome, intrahepatic cholestasis
of pregnancy (ICP), drug-induced liver injury, transient
neonatal cholestasis [TNC], adult biliary fibrosis or cirrho-
sis [3], and very recently intrahepatic cholangiocarcinoma
(IHCC) [4–9].
In young adults, ABCB4/MDR3 alterations are mostly
associated with LPAC syndrome and ICP. In the latter case,
patients typically present with pruritus that can lead to
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complications for both mother and fetus. In the former case,
patients present with intrahepatic biliary lithiasis. The diag-
nosis of LPAC syndrome is often delayed and relies on
clinical and biological elements.
This review will focus on imaging features of hepatobiliary
anomalies associated with ABCB4/MDR3 deficiency in
adults, with special attention to MR characteristics.
Intrahepatic lithiasis
Intrahepatic lithiasis is considered to be very uncommon in
Europe and much more frequent in Asia [10]. Since the de-
scription of MDR3 deficiencies, an increasing number of pa-
tients are diagnosed with LPAC syndrome-related intrahepatic
lithiasis. The diagnosis is frequently performed several years
after the beginning of the symptoms due to their lack of
specificity. The syndrome should be suspected in case of the
association of several elements. The three most important are:
(1) biliary symptoms in a young adult (<40 years old); (2)
symptom recurrence after cholecystectomy; (3) presence of
hyperechoic material in the biliary ducts. Other minor criteria
have been described, such as mild chronic cholestasis, at least
one episode of cholangitis, acute pancreatitis or biliary colic,
efficiency of ursodesoxycholic acid (UDCA) and similar symp-
toms in first-degree relatives.ABCB4 genemutations have been
described in patients with LPAC syndrome in 25–56% of cases
[11–13]. At imaging, LPAC syndrome is associated with vari-
ous MR presentations: normal MR cholangiography, isolated
intrahepatic lithiasis and, rarely, bile duct dilatations. No imag-
ing differences can be found between patients with or without
ABCB4 mutation and no specific mutation can be associated
with the different presentations [12, 14].
The most common presentation of LPAC syndrome is
isolated intrahepatic lithiasis. In LPAC patients, most stones
are referred to cholesterol “yellow” stones. Cholesterol stones
may vary in colour from light-yellow to dark-green or brown.
To be classified as such, they must be at least 50% cholesterol
by weight [15] (or 70 %, according to the Japanese classifi-
cation system) [16, 17]. They may also be calcium bilirubinate
“brown” stones (pigment stones) [18]. Those are traditionally
favoured by bile infection, frequent in the Asiatic population
but much rarer in western countries.
Ultrasound examination is very accurate in detecting
intrahepatic stones, since they appear as heterogeneous and
echoic foci centred on the intrahepatic ducts, or as a “comet-
Fig. 1 Ultrasound/MRCP
discrepancy in a 44-year-old
man with LPAC syndrome. a
Transverse ultrasound showing
typical comet-tail artefacts in
the left lobe. b The MRCP
shows no sign of biliary stone
Fig. 2 Unifocal mild biliary dilatation with biliary stone in a 40-year-
old man with LPAC syndrome. The dilatation is located in the segment
V on T2-weighted acquisitions (white arrow in a) and 3D MRCP (b)
and contains a small signal void corresponding to an endoluminal stone
(white arrow in b). The gallbladder and the common bile duct show no
abnormalities
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tail” artefact due to ultrasound reverberation (Fig 1) [19,
20]. The artefact is not mobile, as opposed to pneumobilia.
The “comet-tail” artefact may be due to intrahepatic lithiasis
or to the associated cholangiopathy.
If endoscopic retrograde cholangiopancreatography
(ERCP) has been considered as the “gold standard”
for diagnosing bile duct stone, magnetic resonance
cholangiopancreatography (MRCP) is a non-invasive
alternative technique that has been shown to be equiv-
alent to ERCP in choledocholithiasis diagnosis and
superior to ERCP in intrahepatic lithiasis diagnosis
[21–23]. The diagnosis of biliary stone is based on
the presence of round or oval shape signal voids in
the lumen of the bile ducts on heavily T2-weighted
sequences (Figs. 2, 3, 4, 5, 6 and 7). However, it is
occasionally difficult to diagnose stones when the sur-
rounding liquid is not present. On T1-weighted sequences,
stones present with a spontaneous hyperintensity and, recent-
ly, studies have shown the superiority of these sequences over
the T2-weighted sequences for the detection of biliary stones
[24]. Discrepancies between MR and ultrasound have been
reported as MR is not able to detect very small stones (Fig 1),
while ultrasound may be suboptimal in case of massive
intraluminal stones (Fig 7). A complementary exploration by
ultrasound and MR should be recommended.
Computed tomography (CT) performance for the diagnosis
of intrahepatic lithiasis depends on the calcium content of bile
stones. Cholesterol stones present with a typical hypodense
aspect and are poorly visible. MR and ultrasound are superior
to CT is such cases.
Fig. 4 Bisegmental dilatation in a 36-year-old woman with LPAC
syndrome. Transverse T1-weighted acquisition with fat saturation after
injection of a gadolinium chelate at portal phase (a and b), and 3D
MCRP (c) show a mild biliary dilatation of both segment III (white
arrow in a) and VI (white arrow in b). The MRCP shows a round
signal void in the dilated bile ducts of the segment III (white arrow in
c) corresponding to a biliary stone
Fig. 3 Severe unisegmental dilatation with endoluminal stones in a
44-year-old woman with LPAC syndrome. Several dilated bile ducts in
segment VIII containing macroscopic signal voids corresponding to
biliary stones (white arrows). a Transverse T2-weighted acquisition
with fat saturation and (b) 3D MCRP
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Bile duct dilatations
When bile duct dilatations are present, they appear as mild
to moderate. Rarely, patients may present with more severe
dilatations (<10 %) [14]. Such severe bile duct dilatation
Fig. 6 Segmental dilatation of segment VI bile duct filled with several
stones in a 69-year-old man with LPAC syndrome. Coronal maximum
intensity projection MCRP (a), transverse T2-weighted acquisition (b),
and transverse in-phase T1-weighted acquisition (c) show a dilatation
of segment VI bile ducts filled with several stones (white arrow in a).
The stones appear as endoluminal signal voids on T2-weighted acqui-
sition (white arrow in b) and hypointensities on T1-weighted acquisi-
tions (white arrow in c)
Fig. 5 Diffuse global bile duct abnormalities in a 48-year-old man
with LPAC syndrome. Transverse T2-weighted acquisition (a), trans-
verse T1-weighted acquisition with fat saturation (b), and coronal
maximum intensity projection MCRP (c) show a biliary dilatation in
both right and left lobes containing biliary stones depicted as T2
hypointense and T1 hyperintense endoluminal formations (white arrow
in a and b). The MRCP shows large oval shape signal voids in the
dilated bile ducts (white arrow in c) corresponding to biliary stones
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may only involve one or two liver segments or may be
diffuse (Figs. 3, 4, 5, 6 and 7). In such cases, and as
opposed to ductal plate malformations (Caroli disease,
congenital hepatic fibrosis, congenital cystic anomalies
of the common bile duct, etc.), which are directly related to
abnormal embryological development of the bile ducts, ab-
normalities are related to a biliogenesis disorder developed
on initially normal ducts. Anomalies are a consequence
of the chronic alteration of the bile composition, which
results in damage to the biliary epithelium. Bile duct
abnormalities are demonstrated as unifocal or multifocal
non-cystic large spindle-shaped bile duct dilatations [14]
(Figs. 2, 3, 4, 5, 6 and 7). However, ductal plate
malformations, particularly the Caroli disease, have to
be ruled out by the absence of specific features, such as
the “central dot sign”, dilated bile ducts associated with
focal area of cystic ectasia, or the fact that no biliary
dilatation can be found in LPAC syndrome without
underlying biliary stones [14, 25]. Other possible differ-
ential diagnosis is bile duct dilatations related to focal
obstacle on the biliary ducts. Traditionally, downstream-
acquired stenosis (iatrogenic, biliodigestive anastomosis,
sclerosing cholangitis, cholangiocarcinoma) may lead to
obstructive dilatations that appear more central without
intrahepatic lithiasis [14].
Cholangitis
In mice, the multidrug resistance (MDR) glycoproteins that
mediate the translocation of phosphatidylcholine across the
canalicular membrane of the hepatocyte are called MDR2.
Whereas the main feature in MDR2 knock-out mice, which
corresponds to the equivalent animal model of human
MDR3 deficiency [26, 27], is sclerosing cholangitis, con-
troversies exist whether a genetically determined dysfunc-
tion of MDR3 plays a pathogenic role in primary biliary
cirrhosis and primary sclerosing cholangitis (PSC) in
humans. Pauli-Magnus et al. [28] found no genetic argu-
ment supporting the role of MDR3 in PSC. Since then,
concepts in PSC understanding have evolved and many
authors consider that PSC may represent a mixed bag of
diseases of different aetiologies in which several genes such
as ABCB4/MDR3 may play a disease modifier role [29]. To
support this conceptual view, our group recently reported for
the first time, in a series of 13 patients with MDR3
Fig. 8 Biliary irregularities in a
54-year-old man. Three-
dimensional MRCP (a) and
sagittal ultrasound of the right
lobe (b) show right biliary
abnormalities (a). These mild
irregular calibre intrahepatic bile
ducts were not demonstrated
with ultrasound; on the other
hand, small bile stones were
easily depicted as hyperechoic
formations with posterior
attenuation
Fig. 7 Severe LPAC syndrome in a 55-year-old man. Transverse T2-
weighted acquisition (a), and coronal maximum intensity projection
MCRP (b) show a rare presentation of severe LPAC syndrome
consisting in diffuse biliary dilatation containing multiple biliary
stones
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deficiency, imaging presentations mimicking sclerosing
cholangitis in two patients at MR imaging [30] (Figs. 8
and 9). They corresponded to small duct fibro-obliterative
lesions at pathology, and may be due to the direct toxic
effect of biliary acids on epithelium. To our knowledge, this
is the only report of such association of MDR3 deficiency
and secondary sclerosing cholangitis but the two patients
presented with recurrent cholangitis and not LPAC syn-
drome per se.
Complications
All complications associated with chronic cholangitis and/or
cholelithiasis have been described in patients with LPAC
syndrome: intrahepatic cholangiocarcinoma (IHCC)
(Fig. 10), portal hypertension, cholangitis and abscess
formation (Fig 11), hepatic fibrosis or cirrhosis. IHCC is
a rare primary liver tumour (10-20 %) [31, 32]. Several
risk factors have been identified and differ in western and
Asian populations: primary sclerosing cholangitis, con-
genital biliary abnormalities and hepatolithiasis [32]. In
most cases, no underlying risk factor is found. Recently,
Tougeron et al. [9] reported two cases of IHCC in differ-
ent and unrelated families with MDR3 deficiency. In both
cases, no argument supporting the direct relation between
ABCB4 mutations and tumorigenesis was found and
IHCC may be considered as a consequence of the chronic
biliary abnormalities. Genetic polymorphisms in biliary
transporters genes have been studied but, to date, no
relation has been established between IHCC and ABCB4
mutations [4].
Fig. 9 Diffuse and severe cholangitis in a 64-year-old woman. Max-
imum intensity projection coronal MRCP (a), T1-weighted transverse
acquisitions with fat saturation after gadolinium chelate injection
obtained at arterial (b), portal (c) and delayed phase (d) show biliary
irregularities and stenoses (a) associated with intense biliary contrast
uptake of the thickened biliary walls at the arterial (white arrows in b)
and portal phase (white arrow in c). The common bile duct presents
with the same abnormalities (white arrow in d). Note the segment I
hypertrophy (white star in b and c)

Fig. 10 Severe LPAC syndrome with secondary intrahepatic
cholangiocarcinoma formation in a 55-year-old woman. Maximum
intensity projection coronal MRCP (a), and transverse T2-weighted
acquisition show right biliary irregularities and dilated left bile ducts
filled with several small intrahepatic stones (white arrow in b). Two
years later, T1-weighted transverse acquisitions with fat saturation after
gadolinium chelate injection obtained at portal phase (c) and transverse
T2-weighted acquisition (d) show an intrahepatic large mass with
irregular contrast enhancement (white star). Liver biopsy confirmed
the diagnosis of intrahepatic cholangiocarcioma

336 Insights Imaging (2013) 4:331–338
Conclusion
LPAC syndrome is the main hepatic condition associated
with ABCB4/MDR3 in adults. It is mainly characterised by
intrahepatic lithiasis and, in severe forms, by bile duct di-
latations and rarely, secondary cholangitis.
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